Related Experiment Videos
[New experimental therapies for type I allergy]
1Institut für Klinische Chemie und Biochemie, Universitätsklinikum Rudolf Virchow, Berlin.
Immunitat Und Infektion
|June 1, 1994
Summary
This study explores therapeutic strategies for allergic responses by targeting CD4+ T cells and their cytokine production. It reviews existing drugs and novel approaches to modulate immune responses in allergies.
Area of Science:
- Immunology
- Allergy Research
- T cell Biology
Context:
- Immediate-type allergic responses involve CD4+ T cells.
- Allergic patients show skewed cytokine profiles (elevated IL-4, reduced IFN-gamma).
- Existing therapies aim to correct immunological dysregulation.
Purpose:
- To review current immunomodulatory drugs (methotrexate, cyclosporine, IVIG) for allergy treatment.
- To present novel therapeutic strategies targeting cytokine production and regulation.
- To discuss experimental approaches modulating T cell activity, such as peptide treatment in animal models.
Summary:
- CD4+ T cells and their cytokine imbalance (IL-4/IFN-gamma) are central to allergic reactions.
- The article examines established immunomodulatory drugs and innovative therapies.
- Experimental methods focus on selective cytokine interference and T cell functional modulation.
Impact:
- Provides an overview of therapeutic interventions for allergic diseases.
- Highlights potential new treatments for immune dysregulation in allergies.
- Discusses the modulation of T cell-mediated allergic responses.